Children have long been an underserved population in the technology space, often having to deal with medical devices that were never designed for them and lack of access to diagnostics and therapeutics that meet their specific needs. The Consortium for Technology & Innovation in Pediatrics, an FDA-funded pediatric medical device accelerator centered at Lurie Children’s and CHLA, aims to change that by supporting pediatric device innovators from concept to commercialization through funding, advising, networking, and advocacy.
Our 8th Annual Catalyzing Pediatric Innovation (CPI) Grant Competition will provide non-dilutive funds ranging from $25,000-$50,000 to pediatric medical device projects at any stage of development. Applications from startups, industry, and academia are welcome. Award recipients will also be eligible to receive CTIP’s wrap-around services to support their journey towards commercialization.
Letters of intent will be considered by the CPI Grant Committee. Based on the comparative merits of all proposals submitted, the most qualified proposals will be designated as finalists. Finalists will be invited to submit a full application.
Eligibility requirements for the Catalyzing Pediatric Innovation (CPI) Grant include the following:
No. Applications are encouraged from both companies and academic institutions. Funding decisions are based on the merit of the project and feasibility of the milestones with respect to funding.
Maybe. There are specific rules from the FDA about the timing and amount of funding companies, groups, or individuals can receive from multiple PDCs. If you have previously received any form of direct funding or monetary grant from another FDA Pediatric Device Consortium for a specific technology or medical device, please contact us via info@westcoastctip.org first before submitting your Letter of Intent.
No. Companies, groups, or individuals that have previously received any form of direct funding or monetary grant from another FDA Pediatric Device Consortium for a specific technology or medical device are not eligible to apply to fund that particular technology or medical device.
Unfortunately, only projects taking place in the US are eligible to apply for this grant. Funding from the FDA cannot be given to non-US entities.
Any company, group or individual working on the development of an innovative pediatric (but not fetal) medical device or technology within the US is eligible to apply.
No, the grant must be used for direct costs. Overhead and indirects are not eligible for funding.
Yes. All research projects that involve human subjects research must be submitted and approved by an Institutional Review Board (IRB) prior to initiation of the research. All research projects that involve animal research must be submitted and approved by the Institutional Animal Care and Use Committee (IACUC) prior to initiation of the animal experiments.
No. These grants are limited to pediatric innovations. The FDA do not classify fetal technologies under pediatric devices/technologies.
No. The grant is intended to fund novel pediatric medical devices or technologies, not for testing of existing devices.
No. For our grant competition, we are looking for novel solutions addressing pediatric needs. Validation or repurposing of adult technologies/medical devices for pediatric applications does not meet this criteria.
Yes. Project applicants, regardless of ultimate funding decision, may be eligible for additional types of support through CTIP. Available support includes consulting services for regulatory assistance, business plan development, grant writing, competitive analysis, reimbursement strategy, biostatistics, and prototype design.
Both are welcome. Funding decisions are based on the merit of the project and feasibility of the milestones with respect to funding. The key criterion is that projects be a pediatric medical device or technology innovation that leads to improved patient experience, quality, outcomes, or efficiency.
No. All intellectual property belonging to the innovator or company will remain its own property irrespective of funding decision.
